Abilify, developed by Otsuka jointly with Bristol-Myers Squibb, was approved by the Food and Drug Administration (FDA) for treatment of acute manic and mixed episodes in children aged 10-17 associated with bipolar disorder.
The FDA has given the approval on the basis of four-week-study results. The drug showed effectiveness compared to a placebo.
The drug was first approved on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind in adults.
In a weary world of endless US military interventions, sanctions, trade tariffs and chaos, let’s pause and take stock of the shining house on the hill